<DOC>
	<DOC>NCT00811902</DOC>
	<brief_summary>The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS). Secondary objectives: - To assess other measures of walking ability, tiredness, and lower limb muscular strength, spasticity, clinical assessment by subject and clinical assessment of change by the Study Investigator - To assess the safety and tolerance of nerispirdine - To evaluate the pharmacokinetics (PK) parameters of nerispirdine</brief_summary>
	<brief_title>Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis</brief_title>
	<detailed_description>Total duration per patient is approximately 19 weeks in total, comprising a 3-week screening period inclusive of a 2-week placebo run-in period, a 14-week treatment period, and a 2-week placebo run-out (follow-up) period</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Clinically definite MS (according to McDonald criteria), Multiple sclerosis exacerbation or clinical relapse within 6month prior to the screening visit. Subject who is not able to complete two trials of a timed 25 foot walk, with or without an assisted device, Patients without valid V1, V2, and V4 T25FW measurements are not eligible for randomization. Female patients who are either pregnant or breastfeeding. Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
</DOC>